NCT03628222 is a NA clinical trial of ENB-TBLB in Lung Lesion(s) Requiring Evaluation, sponsored by Changzhou LungHealth Medtech Company Limited.

Who is sponsoring NCT03628222?

NCT03628222 is sponsored by Changzhou LungHealth Medtech Company Limited.

What drugs are being tested in NCT03628222?

Interventions in NCT03628222: ENB-TBLB, X-ray-TBLB.

What condition does NCT03628222 study?

NCT03628222 studies Lung Lesion(s) Requiring Evaluation.

Is NCT03628222 still recruiting?

NCT03628222 is currently completed. Last updated 23 August 2024.

Last reviewed 2024-08-23 · How we verify

NCT03628222

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transbronchial Lung Biopsy Guided by ENB

Completed NA Last updated 23 August 2024

What this trial tests

NA trial testing ENB-TBLB in Lung Lesion(s) Requiring Evaluation in 226 participants. Completed in 10 August 2020.

Timeline

4 January 2019

Primary endpoint
30 July 2020

10 August 2020

Quick facts

Lead sponsor	Changzhou LungHealth Medtech Company Limited
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	226
Start date	4 January 2019
Primary completion	30 July 2020
Estimated completion	10 August 2020
Sites	8 locations across China

Drugs / interventions tested

ENB-TBLB
X-ray-TBLB

Conditions studied

Lung Lesion(s) Requiring Evaluation — all drugs for Lung Lesion(s) Requiring Evaluation →

Sponsor

Changzhou LungHealth Medtech Company Limited

Who can join

18 and older, any sex, with Lung Lesion(s) Requiring Evaluation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the performance and safety of electromagnetic navigation bronchoscopy (ENB) system and system kit (iLungTM SuperNavigator) .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03628222 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changzhou LungHealth Medtech Company Limited
Last refreshed: 23 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03628222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing